Rifaximin Treatment of Papulopustular Rosacea

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Rosacea

In brief

The purpose of this study is to determine the effects of rifaximin on skin symptoms in patients with rosacea by double-blinded, placebo-controlled, crossover study.

Key facts

Study ID

NCT01359228

Run by

University of California, San Francisco

People needed

0

Starts

2013-04-01

Expected to finish

2014-12-01

Last updated by the study team

2014-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females
• > 18 years of age with rosacea defined as:
• 3-40 papules/pustules and < 2 nodules,
• A score of 2-4 on the Investigator Global Assessment

You may not qualify if…

• Untreated pancreatic insufficiency
• Crohn's disease
• Ulcerative colitis
• Active celiac disease by clinical history
• End stage renal failure
• Less than 18 years old
• Pregnancy or positive pregnancy test
• Rosacea subtype 1 (no papules )
• Topical or oral antibiotics within 4 weeks
• Acne treatments within 4 weeks prior to randomization
• Systemic retinoids within 90 days
• Topical or systemic corticosteroids 4 weeks prior to randomization

Where it is running

• UCSF, CTSI, 12-Moffitt/Long Hospital — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.